San Diego-based Organovo (NASDAQ: ONVO), which specializes in 3D biological printing technology, said Tuesday its board has named Taylor J. Crouch to succeed Keith Murphy as CEO. According to a statement from the company, Murphy, who co-founded Organovo in 2007, is “stepping down as chief executive officer to pursue entrepreneurial opportunities, effective April 21.” He will continue to serve as Organovo board chairman.
Crouch’s prior experience in leading a group of clinical research companies suggests that Organovo is focusing its strategy more specifically on providing 3D-cell cultures to pharmaceutical companies for pre-clinical drug testing. He was previously the CEO of eStudySite—which operates clinical research sites in San Diego, San Francisco, and Las Vegas—from 2009 to mid-2016. Crouch was also executive chairman of Meridien Research from 2013 to 2016, and as a director of the National Research Institute from 2011 through mid-2016.
Before that, Crouch served as a senior vice president of operations at San Diego’s Ligand Pharmaceuticals; as president of Ligand’s international business; as chief operating officer at Discovery Partners International; and as CEO of Variagenics.